Across Europe , ACE-031, in its 1mg dose , is emerging as a potential treatment for specific brain disorders . Clinical trials in nations such as Germany and France are focusing on its check here efficacy on clinical results . Agencies throughout the area are observing the development of ACE-031, with possible authorization expected to rely on the